Study type: In vivo/preclinical · Status: Verified against declared source
Cathelicidin hCAP18/LL-37 promotes cell proliferation and suppresses antitumor activity of 1,25(OH)2D3 in hepatocellular carcinoma
2022
Study scale: Not reported
Abstract only: Open source record
Product or molecular entity relationships
- LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Cathelicidin hCAP18/LL-37 can resist infection from various pathogens and is an essential component of the human immune system.
Methods
Not reported in the reviewed source.
Scale or participants
Not reported in the reviewed source.
Key findings
Cathelicidin hCAP18/LL-37 can resist infection from various pathogens and is an essential component of the human immune system.
Limitations and uncertainty
Cathelicidin hCAP18/LL-37 can resist infection from various pathogens and is an essential component of the human immune system.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.